Glipada 50/500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which in turn stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control by addressing multiple pathophysiological defects associated with type 2 diabetes. Glipada 50/500 is typically prescribed when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated but may rarely cause hypersensitivity reactions. Glipada 50/500 should be used under medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes and minimize potential risks.